

Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer



Shangze Li, Ka-wing Fong, Galina Gritsina, Ali Zhang, Jonathan C. Zhao, Jung Kim, Adam Sharp, Wei Yuan, Caterina Aversa, Ximing J. Yang, Peter S. Nelson, Felix Y. Feng, Arul M. Chinnaiyan, Johann S. de Bono, Colm Morrissey, Matthew B. Rettig, and Jindan Yu

In the original version of this article (1), the same image was inadvertently duplicated in Fig. 5J, column #2. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Reference

1. Li S, Fong K, Gritsina G, Zhang A, Zhao J, Kim J, et al. Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer. *Cancer Res* 2019;79:2580–92.

Published online May 15, 2020.

Cancer Res 2020;80:2072

doi: 10.1158/0008-5472.CAN-20-0768

©2020 American Association for Cancer Research.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer

Shangze Li, Ka-wing Fong, Galina Gritsina, et al.

Cancer Res 2020;80:2072.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/80/10/2072>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/80/10/2072.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/80/10/2072>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.